NCT03413579View on ClinicalTrials.gov

Evaluate Efficacy of the Association Nimotuzumab(HR3) /Cisplatin-Vinorelbine on Patients With Cervical Carcinom

PHASE3CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

March 31, 2020

Study Completion Date

February 28, 2021

Conditions
Cervical Cancer
Interventions
BIOLOGICAL

Nimotuzumab ( h-R3)

Humanized monoclonal antibody

OTHER

Placebo

Trial Locations (5)

Unknown

Centre Pierre et Marie Curie (CPMC), Algiers

CAC Annaba, Annaba

CAC Batna, Batna City

CHU Frantz Fanon, Blida

CHU Sidi Belloua, Tizi Ouzou

All Listed Sponsors
lead

El Kendi Pharmaceuticals Manufacturing Company

INDUSTRY

NCT03413579 - Evaluate Efficacy of the Association Nimotuzumab(HR3) /Cisplatin-Vinorelbine on Patients With Cervical Carcinom | Biotech Hunter | Biotech Hunter